AbbVie Inc. $ABBV Shares Acquired by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in AbbVie Inc. (NYSE:ABBV) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,207 shares of the company’s stock after purchasing an additional 2,833 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in AbbVie were worth $8,273,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ellenbecker Investment Group boosted its stake in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after buying an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA increased its stake in shares of AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC increased its stake in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the period. Centennial Wealth Advisory LLC raised its holdings in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after acquiring an additional 45 shares in the last quarter. Finally, Willner & Heller LLC raised its holdings in AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after acquiring an additional 46 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Down 1.3%

Shares of AbbVie stock opened at $214.72 on Thursday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm’s 50 day moving average is $221.98 and its two-hundred day moving average is $224.58. The firm has a market capitalization of $379.66 billion, a P/E ratio of 90.98, a P/E/G ratio of 0.76 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the firm earned $2.16 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Federal tax-law effects: Analysts and reports show U.S. corporate cash taxes fell roughly $65B after recent tax changes, a trend benefiting large pharma cash flow and near-term free cash flow for companies like AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Positive Sentiment: Allergan Aesthetics promotion: AbbVie’s aesthetics unit is running its fourth annual CoolMonth promotion (CoolSculpting offers), which can modestly boost procedure volumes and near-term aesthetics revenue. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
• Neutral Sentiment: Earnings schedule: AbbVie set its Q1 2026 results release and conference call for April 29 (pre-market), a scheduled event that will be the next major catalyst for stock direction. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Mixed intraday moves: Recent headlines show short-term intraday swings (some sessions with gains, others with underperformance versus the market), indicating investor attention is currently fragmented between fundamentals and newsflow. AbbVie Inc. stock rises Tuesday, still underperforms market AbbVie (ABBV) Gains As Market Dips: What You Should Know
• Negative Sentiment: Litigation tied to Cerevel/AbbVie deal: A court ordered Pfizer and Bain to litigate a suit by Cerevel investors over the AbbVie transaction, creating deal-related legal uncertainty and potential distraction or liabilities. That legal cloud can pressure sentiment around transactions and M&A strategy. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds: Analyst commentary flags likely 2026 revenue pressure in AbbVie’s oncology franchise — pricing pressure on Imbruvica and a near-term dip in legacy oncology sales could offset growth from newer oncology assets. This is a direct revenue-risk item investors care about for 2026 guidance. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?

Wall Street Analysts Forecast Growth

ABBV has been the subject of several analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Evercore lowered their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.